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Background: Due to advances in multimodal therapies, most children survive cancer. In addition to the stresses of
diagnosis and treatment, many families are now navigating the challenges of survivorship. Without sufficient
support, the ongoing distress that parents experience after their child’s cancer treatment can negatively impact the
quality of life and psychological wellbeing of all family members.
Methods/Design: The ‘Cascade’ (Cope, Adapt, Survive: Life after CAncEr) study is a three-arm randomised
controlled trial to evaluate the feasibility and efficacy of a new intervention to improve the quality of life of
parents of young cancer survivors. Cascade will be compared to a peer-support group control and a 6-month
waitlist control. Parents (n = 120) whose child (under 16 years of age) has completed cancer treatment in the past
1 to 12 months will be recruited from hospitals across Australia. Those randomised to receive Cascade will
participate in four, weekly, 90-minute online group sessions led live by a psychologist. Cascade involves peer
discussion on cognitive-behavioural coping skills, including behavioural activation, thought challenging,
mindfulness and acceptance, communication and assertiveness skills training, problem-solving and goal-setting.
Participants randomised to peer support will receive four, weekly, 90-minute, live, sessions of non-directive peer
support. Participants will complete measures at baseline, directly post-intervention, one month post-intervention,
and 6 months post-intervention. The primary outcome will be parents’ quality of life. Secondary outcomes
include parent depression, anxiety, parenting self-agency, and the quality of life of children in the family. The
child cancer survivor and all siblings aged 7 to 15 years will be invited to complete self-report quality of life
measures covering physical, emotional, social and school-related domains.
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Discussion: This article reviews the empirical rationale for group-based, online cognitive-behavioural therapy in parents
of children who have recently finished cancer treatment. The potential challenges of delivering skills-based programs
online are highlighted. Cascade’s videoconferencing technology has the potential to address the geographic and
psychological isolation of families after cancer treatment. Teaching parents coping skills as they resume their normal lives
after their child’s cancer may see long-term benefits for the quality of life of the family as a whole.
Trial registration: ACTRN12613000270718 (registered 6 March 2013).
Keywords: Parent, carer, cancer, survivorship, intervention study, randomised controlled trial, psychological adaptation,
quality of life, cognitive-behavioural therapy, Internet, E-healthBackground
Although rare, cancer is a leading cause of death in chil-
dren in developed countries [1]. After the shock of diagno-
sis, parents face the difficult dual challenges of supporting
their child through debilitating treatment, whilst grappling
with the possible death of their child [2]. Due to improved
multimodal therapies, most children survive cancer [3]. It is
often only when treatment ends that parents process the
experience, at the very time when hospital-based psycho-
social support is diminished [4]. Despite the acknowledged
positive aspects of treatment completion [5,6], this is a vul-
nerable time for some parents, who can experience worsen-
ing quality of life (QoL), anxiety, depression, and feelings of
helplessness [7,8]. Parents living in rural/remote areas ap-
pear most at risk of these poor outcomes [9]. Major themes
of difficulty in the post-treatment period can include fear of
cancer recurrence, isolation, and loneliness, with substantial
unmet needs for information about relapse surveillance and
how to ‘return to normality’ [10-12].
In the face of cancer, parents may lack the coping
skills needed to manage the demands of their child’s
treatment and survivorship, and others can develop mal-
adaptive coping strategies under pressure [13]. Parental
psychological adjustment problems may jeopardise their
capacity to provide the ‘secure base’ that children need
in times of stress [14] and can lead to less effective par-
enting [15,16]. Even after their child has been cured, dis-
tressed parents may express more anger toward their
surviving child [17], listen less to their children [18], and
have more negative parent–child interactions [19]. These
parenting approaches may result in more behaviour
problems [15] and distress [20,21] in young cancer survi-
vors and their siblings [22]. The impact of poor parent
coping may extend for years, with evidence that even 10
to 15 years post-diagnosis, coping in child cancer survi-
vors may still be related to their mother’s coping [23].
Best-practice mental health interventions for children
with cancer therefore need to target the family, not just
the patient [24].
Evidence-based psychological interventions have the
potential to reduce parental mental health burden in the
‘coming off treatment’ phase, thus curtailing longer-termdifficulties. Best-practice interventions target modifiable
processes associated with parents’ poor adaptation to
their child’s cancer. For example, parents of children
with cancer can use more ruminative thinking and defen-
sive coping strategies [13], both of which can create con-
flict and poor family cohesion [25]. Interventions that
increase parents’ use of adaptive coping strategies in the
face of their child’s cancer may reduce their risk of depres-
sion and anxiety [26] and enhance their parenting skills
[17]. Improving parents’ communication skills can also
promote adaptive functioning in children with cancer [27].
Parents’ capacity to proactively solve problems and seek
help when needed is also modifiable, yielding improved
outcomes for children with cancer when targeted [13,28].
Skills-based interventions can be effective in parents
of children with cancer, yielding medium-large effects
[29]. However, few interventions have been rigorously
evaluated. Most are also implemented face-to-face, limit-
ing benefits to rural and remote families. It is clear that
online cognitive-behavioural therapy (CBT) programs
can be effective, with meta-analyses reporting medium-
large effects for anxiety [30] and depression [31]. Trans-
diagnostic programs that target co-morbid anxiety and
depression may also be effective when delivered online
[32]. Online programs also have the potential to reduce
distress and improve wellbeing in those who care for
someone with a medical condition [33]. Furthermore,
group-based support is cost-effective and provides a
unique context in which individuals can provide each
other with emotional support, reflect on the commonal-
ities of their experiences, and share resources [34]. Given
that no efficacious, online programs currently exist to
provide support for Australian parents at this recognised
critical adjustment period [35], we developed a tailored
intervention, ‘Cascade’, to meet their needs.
Methods/Design
The Cascade study is a multi-site, randomised controlled
trial (RCT) to assess the feasibility and efficacy of a new,
online, CBT-based intervention for the parents or legal
guardians (hereafter referred to as ‘parents’) of young can-
cer survivors (see Additional file 1 for a list of participating
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16 years of age who have completed cancer treatment with
curative intent and achieved remission in the past
12 months will be recruited and randomised to one of three
arms: i) Cascade, ii) a peer-support group (PSG) control, or
iii) a 6-month waitlist control. Informed consent will be ob-
tained from all participants. The 1- to 12-month timeframe
was chosen to maximise the benefit to participants, by de-
livering the coping skills intervention early in their child’s
survivorship period. The intervention, named ‘CASCAdE’
(Cope, Adapt, Survive: Life after CAncEr), is delivered live,
in real-time, to groups of 3 to 5 parents by a psychologist
(hereafter referred to as ‘facilitator’) in four, weekly online
sessions. Participants also receive an online introductory
session with the facilitator before the group commences
and a ‘booster’ session one month after the end of the
group to facilitate consolidation of skills.
Cascade will be compared with the active PSG control
in order to assess the relative benefits of peer-based sup-
port and contact with any additional psychological bene-
fits gained from learning structured, skills-based coping
strategies. ‘Peer-support’ type models of support are ubi-
quitous in community settings, yet few PSGs have been
rigorously evaluated [36]. Consequently, little evidence ex-
ists to support the appropriateness of PSGs alone in ad-
dressing distress in parents of children with cancer. The
PSG arm holds constant the amount of treatment contact,
human interaction variables (such as facilitator warmth
and interaction between participants), as well as control-
ling for participants’ expectations of receiving some form
of treatment [37].Table 1 Assessment schedule for the cascade study
Measure Intake
Psychosocial Adjustment to Illness Scale-Interview form (PAIS) X
Demographic data -
Treatment Intensity Scale -
Medical and general functioningg -
Paediatric Quality of Life Inventory (PedsQL) Generic Core Scaleh -
Paediatric Quality of Life Inventory (Family Impact Module) -
EQ-5D-5 L -
Parenting Self Agency Measure (Revised) -
CBT skills use -
PROMIS parent mental health and functioning short-form itemsi -
California Psychotherapy Alliance Scale - Group (CALPAS-G) -
Intervention satisfaction items -
Emotion Thermometers Tool X
Homework Compliance Scale -
Working Alliance Inventory - Short -
aQ1 = Baseline; bDuring intervention = weekly prior to intervention sessions 2 to 4; c
dQ3 =Week 5 follow-up, eQ4 = 6 month follow-up; fQ5 = after waitlist participants h
gIncluding other psychological support received; hParent proxy and child self-reportThis study employs a three (treatment condition) by
four (assessment point) factorial design. All participants
will complete an assessment battery at baseline (T1: re-
cruitment), immediately after participation in Cascade or
the PSG control (T2), 5-weeks post-intervention/1-week
post-booster session (T3), and 6-months post-intervention
(T4). The waitlist group will be assessed at the same time
points. After the 6-month waitlist period, waitlisted par-
ents will be re-randomised to either Cascade or the PSG.
They will complete a final, additional, assessment battery
immediately after their group program (T5). All the chil-
dren ages 7 to 15 years of participating parents (including
the child cancer survivor and any siblings) will be invited
to complete measures of depression, anxiety and peer rela-
tionships at the same time points as their parents (see
Table 1).
Aims and hypotheses
This RCT aims to assess the following:
1. The feasibility of implementing Cascade nationwide,
including the recruitment procedure, response/
attrition rates and cost.
2. The efficacy of Cascade in improving the QoL of
parents (the primary outcome). Secondary outcomes
include parent depression, anxiety, and parenting
self-agency, as well as social and emotional function-
ing of the children in the family.
We hypothesise that delivering Cascade will be feasible
and acceptable. We also hypothesise the following:Q1a During interventionb Q2c Q3d Q4e Q5f
- - - - - -
X - - - - -
X - - - - -
X - X X X X
X - X X X X
X - X X X X
X - X X X X
X - X X X X
X - X X X X
X - X X X X
- - X - - X
- - X - - X
- X - - - -
- X - - - -
- X - - - -
Q2 = post-intervention.
ave completed the intervention.
; iItems assess parent depression and anxiety symptoms.
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greater improvements in QoL compared with the
waitlist control, measured from T1 to T2.
2. Participants who complete Cascade will show
greater improvements in their QoL compared to
participants who complete the PSG, measured from
T1 to T2.
Participants
This study will recruit 120 parents (approximately 40 in
each arm). This sample size will allow medium-to-large
differences in parent QoL to be detected with a power of
80% at a two-tailed significance level of 0.05 (assuming
Cohen’s d = 0.65 as the difference in change from time 1
to time 2 for any pair of groups, standardised on the
pooled within-group standard deviation). This effect size
is clinically significant [38]. It is anticipated that approxi-
mately 375 parents will need to be approached to
achieve a final sample of 120 participants (assuming a
40% response rate and 20% attrition rate).
Inclusion criteria
Eligible parents will meet the following inclusion criteria:
i) have a child under 16 years of age who has completed
cancer treatment with curative intent in the past
12 months; ii) be able to give informed consent; iii) be able
to read English; iv) be able to provide the contact details
of a trusted health professional, such as their local gen-
eral practitioner; and v) be able to access the Internet in
a private location (see also Access considerations below).
Children will be eligible if they are aged 7 to 15 years
and, in the opinion of the parent, are capable of reading
at a Grade Two level. In this study, we are interested in
parents of young cancer survivors aged less than
16 years, and so we matched siblings to this age range.
Child participants will require parental consent.
Exclusion criteria
Parents will be excluded if, during the initial intake
interview, they i) have insufficient English language skills
to complete the interview; ii) demonstrate very high
levels of distress, anxiety, and/or depression on the Emo-
tion Thermometers Tool (that is, scores ≥ 7) [39] and en-
dorse serious suicidal intent; iii) endorse symptoms of
psychosis or substance abuse; or iv) have a child who is
currently on active treatment, has relapsed, or is in pal-
liative care. Any participant who is excluded will be pro-
vided with appropriate referral options, if desired.
Access considerations
To participate in the study internet access and a suit-
able computer set-up is required. This includes access
to a computer/tablet that has a microphone and web-
camera and can be used privately and uninterruptedonce per week for four weeks. Participants will be
loaned an insured tablet and/or web-camera and inter-
net access USB device if needed (the costs of which are
covered by Cascade’s project grant).
Participant recruitment
Potential parent participants will be mailed an invitation
package comprising a personalised invitation letter from
the Head of Oncology or their child’s treating oncologist
at their child’s treating centre, a consent form, and an opt-
in card, as well as a separate child assent form. The re-
search officer will contact all parents who opt in to assess
their technology needs and, if a loan is required, request
that participants sign and return a written contract agree-
ing to use the equipment solely for study purposes.
Recruitment will occur in 5 × 12 week blocks, such that
approximately 75 parents will be invited 4 weeks prior to
Week 1 of each block. Using our expected response and
attrition rates, it is envisaged that five iterations (that is,
5 × 12 week blocks), each attracting approximately 30 par-
ent opt-ins, will be required to achieve the target sample.
This means that five mail outs (approximately 75 parents
at a time) will occur during 2014/5. All fully consented
participants will be telephoned by the research officer
2 weeks prior to Week 1 to administer the Psychosocial
Adjustment to Illness Scale Interview (PAIS) [40]. Partici-
pants will also complete the first online questionnaire at
this time. See Figure 1 for the study flowchart.
Randomisation
Participants will be randomised to one of the three arms
using a flexible biased urn method of randomisation,
which adapts to the degree of imbalance between groups
in a dynamic manner over the trial [41]. This method is
superior to standard stratification in balancing groups
across multiple covariates [42,43], whilst also being a suit-
able method when groups remain small [41,44,45]. The
groups will be balanced across two factors: i) severity of
distress as measured by the Emotion Thermometers Tool
[39] and ii) degree of rural/remoteness as assessed by the
Accessibility/Remoteness Index of Australia [46]. An inde-
pendent researcher will electronically randomise partici-
pants to treatment group.
Interventions
Cascade
Cascade is guided by the family systems illness model
[47]. This evidence-based framework conceptualises re-
silience in families as a multifaceted process involving
the interaction between negative sequelae (stressors) and
positive responses (coping strategies), with a key role for
family members’ appraisal of the stressor in determining
adaptive coping responses. Cascade derives its proposed
core mechanisms of change from CBT and addresses both
Parents approached for participation, Week -4
Opt-in/consent received








Introductory online session with psychologist
As soon as possible (Week -1)




























Questionnaire 3 (child and parent, T3)
(1 week after booster session, Week 9)
Wait  
Booster Session
(4 weeks post intervention, Week 8)
Wait
Randomised
Questionnaire 1 (child and parent, T1) Week -2
Allocated to Peer 
support group (PSG)
Questionnaire 5 (child and 
parent, T5)
Post intervention (waitlist only)
Complete
CASCADE PSG
Questionnaire 4 (child and parent, T4)
(6 months post intervention, Week 30)
Begin intervention with psychologist
(4 week duration, Weeks 1-4)
Figure 1 Cascade study flowchart.
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particularly effective in improving QoL in carers of cancer
patients if it targets communication and problem solving
skills (both addressed in Cascade) [48]. Each Cascade
module applies CBT techniques to the key domains of
concern identified in our previous research [4,49] (seeTable 2). Our strengths-based approach recognises that
families are resilient and competent [31], which means
that Cascade builds on psychological strengths while miti-
gating negative symptoms in the broadest possible group.
Participants randomised to Cascade will participate in
four, live, weekly, 90-minute sessions facilitated by a






Module 1 ‘What just happened to us?!’ Peer discussion to normalise
range of typical parent
experiences.
Processing the cancer
experience and getting back
to some form of ‘normal’.
Behavioural activation to
improve mood, fatigue, and
activity levels.
Module 2 ‘How has cancer changed
the way I think?’
Peer discussion to normalise
increase in frequency and
intensity of worries after
cancer.
Managing upsetting thoughts






Module 3 ‘Out of your head and back
into life’






based strategies for easing the
struggle with ‘bigger’ existential
concerns and emotional pain.
Practical problem solving
strategies for problems with
logical solution(s).
Cognitive strategies for





Module 4 ‘Looking forward’ Peer discussion to normalise
changes to relationships and
feelings of isolation after the
cancer experience.
Skills for fostering meaningful
relationships, accessing social
support and living a rich and








Booster Individual ‘catch-up’ session
with each parent one month
after the end of the group.
Assist participant to identify
challenging situations in the
past month according to
cognitive-behavioural model,
and review helpful coping
skills.
Review goal from the start of
the program - discuss what
has helped and what remains
challenging in this area.
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and three to five participants with mixed cancer experi-
ences (such as the age of their child and their child’s type of
cancer). Participants also receive a purposely developed
workbook, outlining the content of each session, providing
additional examples and suggesting ‘homework’ activities tofacilitate skill development. Additional files 2, 3 and 4 show
details of the workbook content and graphic design.
Sessions will be delivered through WebEx (Cisco
WebEx, USA). WebEx requires a computer with stand-
ard browser, a high-speed internet connection, and a
webcam. WebEx is a secure, password-protected video-
conferencing program that allows up to six participants
to be seen on the screen simultaneously, similar to
group Skype™. Participants will receive a reminder text
message on their cellular phone 24 hours before their
session, which will also serve as their reminder to
complete the Emotion Thermometers Tool [39] and
homework compliance scale (see Assessments).Peer-support group (active control)
The PSG control is delivered in an identical manner to
Cascade (via WebEx, up to five participants per group),
with the same frequency of contact (four weekly 90-
minute sessions) and availability of peer-based group
discussion. The PSG is delivered by the same facilitator
as Cascade (see Treatment fidelity for further discus-
sion). Like Cascade, it also involves supportive counsel-
ling to normalise the range of parent experiences and
provides parents an opportunity to give and receive
emotional/practical support. During each session, par-
ents are encouraged to exchange information about a
nominated topic (matched to those addressed in Cas-
cade for example, ‘relationships and social support’). The
key distinction between Cascade and the PSG is that the
PSG does not include directive, structured teaching of
specific, CBT-based coping skills. The PSG in this trial
will adhere to best practice guidelines [50] and is man-
ualised to ensure standardisation across all sessions.Procedures
Following recruitment, participants will complete a tele-
phone intake interview with a Cascade research officer
to further screen for participant eligibility, orient partici-
pants to the study procedures, ascertain any technical
needs, and complete the PAIS [40].
Participants will then be randomly allocated to a
study arm. During Weeks 1 to 4 of each 12-week block,
those allocated to Cascade and the PSG will participate
in their allocated intervention. Waitlist controls will be
assessed at the same time points as the intervention
groups, and will be randomly allocated to either Cas-
cade or PSG during weeks 26 to 30. The waitlist group
will also complete a final questionnaire (Q5) after par-
ticipating in the intervention. Parents will be sent links
via email to complete the questionnaires (see Data
management and analysis) and will be encouraged to
supervise their child/ren while they complete the ques-
tionnaires, if desired.
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This study is listed on the Australian New Zealand Clin-
ical Trials Registry ACTRN12613000270718, and has
undergone rigorous multidisciplinary peer and consumer
review. It is endorsed by the Australian New Zealand
Children’s Haematology Oncology Group (ANZCHOG).
Ethical approval has been obtained from Sydney
Children’s Hospital, Children’s Hospital at Westmead,
Royal Children’s Hospital Melbourne, Monash Children’s
Hospital Melbourne, Queensland Children’s Cancer Centre,
Women’s and Children’s Hospital Adelaide, and the Royal
Adelaide Hospital. This study complies with the CON-
SORT guidelines [42] by using the following: a) standar-
dised assessment measures; b) blind assessments; c)
standardised assessor training and inter-rater reliability
checks; d) manualised, replicable procedures for all condi-
tions; e) random allocation; and f) treatment fidelity
checks.
Treatment fidelity
Both treatment groups will be facilitated by the same per-
son to prevent confounds (for example, attributes such as
age, sex and communication style), each of which could
impact group retention/efficacy. Any variation or system-
atic biases between groups will be detected and corrected
by the independent assessors during treatment fidelity
checks of a random 15% of all video-recorded sessions
(the validated ‘Method of Assessing Treatment Delivery’
advises a minimum of 11%) [51]. All pre- and post-
treatment outcome measures will be administered by the
research officer, who will be blind to group allocation. In
compliance with the CONSORT guidelines, the research
officer will report on which condition they believe each
participant was in at the end of the study.
To ascertain why this intervention may not be toler-
ated by all parents, exit interviews will be collected for
all who leave the study prematurely, as well as for 15%
of those who complete the intervention to collect in-
depth data on participants’ likes and dislikes and to so-
licit ideas for improvement.
Safety monitoring
This trial includes safety monitoring and management
procedures at multiple project stages (see Figure 2).
The intake interview carefully screens for acutely sui-
cidal/severely depressed participants. Participants will
also be regularly screened for mood deterioration dur-
ing intervention participation when they complete the
weekly Emotion Thermometers Tool [39] (see Assess-
ments). Any deterioration in mood of more than three
points on the tool will trigger protocols involving the
facilitator contacting the participant to discuss their
emotional state and a meeting between the researchers




The feasibility of Cascade will be determined by recording
the (i) time taken to recruit sufficient participant numbers,
(ii) proportion of participants who required loaned technol-
ogy, (iii) time taken to complete and return questionnaires,
(iv) study response rate (feasible at 40%), (v) attrition rates
of each arm (feasible at 20%), and (vi) proportion of chil-
dren who participate. Feasibility will also be assessed by
examining the flow-through of the study (from opt-in to
final questionnaire completion), using medians and ranges.
Demographic measures
Table 1 summarises the planned assessments. Information
on parent age, sex, education, employment status, and fam-
ily structure will be collected, as well as information on the
child’s diagnosis and treatment regimen using standardised
items adapted from the Childhood Cancer Survivor Study
[52]. Information such as whether the child relapsed or re-
ceived a bone marrow transplant will be obtained. This data
will be sufficient for a qualified paediatric oncologist to
grade the child’s treatment intensity according to the vali-
dated Treatment Intensity Scale [53] will be included in
order to assess the severity/intensity of the child survivor’s
medical treatment. Information on the gender and age of
all child participants will be obtained. Parent participants
will also be asked to report on all forms of psychological
support accessed at each time point.
Parent/caregiver psychosocial functioning
There is little consensus regarding the relative superiority
of generic versus disease-specific psychosocial measures in
psycho-oncology. Disease-specific measures often appeal
to researchers due to the difficulty ascertaining ‘clinical’
change in populations that may only be distressed at sub-
clinical levels [54,55]. However, generic psychological
measures facilitate comparison to healthy norms, which
can be clinically and empirically advantageous [56]. As
such, the Cascade trial uses both generic and disease-
specific indicators of psychosocial functioning.
The Pediatric Quality of Life inventory (PedsQL)
Family Impact Module [57] was selected as the primary
psychosocial outcome variable as it assesses parent/
caregiver functional concerns specifically related to
their child’s illness. Four purposefully developed and
pilot-tested items were also added to specifically index
parents’ concerns (if any) about their child’s cancer recur-
ring. The widely-used EQ-5D-5 L [58] is a generic measure
that will assess parents’ wellbeing in five domains: mobility,
self-care, engagement in usual activities, physical pain/dis-
comfort and anxiety/depression.
Figure 2 Cascade safety monitoring procedures.
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Interview Form (PAIS) [40] will be administered over
the telephone. The PAIS assesses adjustment of pa-
tients and parents/carers to illness across seven do-
mains: health care orientation, vocational environment,
domestic environment, sexual relationships, extended
family relationships, social environment and psycho-
logical distress.
The Parent Self-Agency Measure (Revised) [59] provides
an index of parents’ general confidence in their parenting
behaviours. Parenting competence is of interest in Cascadedue to its bi-directional relationship with child develop-
ment and adjustment outcomes. Importantly, parents’
confidence in their ability to parent and associated positive
parenting practices may be a protective factor for families
under stress [60].
Finally, items from the Patient-Reported Outcomes
Measurement Information System (PROMIS) short-form
questionnaires will be used to assess depression and anx-
iety symptomology. PROMIS has excellent psychometric
properties superior to many other measures available to
assess emotional functioning [61].
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The Paediatric Quality of Life Inventory (PedsQL) Gen-
eric Core [62] parent proxy-report scale will be used to
assess the cancer survivor’s quality of life in physical,
emotional, social, and school-related domains of func-
tioning. In a recent review of QoL measures for children,
the PedsQL emerged as a feasible and valid tool that is
widely used in cancer and chronic disease [63]. All par-
ticipating children (the child survivor and/or any siblings)
will also complete a child self-report version of the scale.
Intervention engagement and impact
To assess participants’ mood in a more dynamic manner
across the intervention, parents will complete the Emo-
tion Thermometers Tool [39] each week, 24-hours prior
to participating in their weekly session (Cascade or
PSG). At the same time, parents will complete the 6-
point Homework Compliance Scale [64] to assess com-
pliance with the home practice exercises. CBT skills used
will also be assessed using 10 purposely developed and
pilot-tested items; for example, assessing participants’
ability to ‘recognise unhelpful thoughts and how they
are making me feel’ (response options range from ‘not at
all’ to ‘a lot’). The Working Alliance Inventory - Short
(WAI- S) [65] and The California Psychotherapy Alli-
ance Scale - Group (CALPAS-G) [66] will be used to as-
sess participants’ perceptions of the therapeutic working
alliance, during and after the intervention.
Satisfaction with intervention
After participating in Cascade or the PSG, parents will
provide ratings of specific intervention elements to de-
termine their acceptability. Open-ended questions will
also be used to elicit views about the benefit and/or bur-
den of participating and suggestions for improvement.
Data management and analysis
All measures (excluding the PAIS telephone interview) will
be administered online through Key Survey (WorldAPP,
Braintree, MA, USA) at all time points, unless paper ver-
sions are requested by participants. Key Survey enables par-
ticipants’ data to be securely downloaded to files amenable
to statistical analysis using the Statistical Package for the
Social Sciences, version 18.0 (SPSS, Inc., Chicago, IL, USA).
Statistical analyses
This trial will employ ‘intention-to-treat’ and ‘as-treated’
analyses. Analyses will be based on mixed random-
intercept models that will assess differences between the
groups in terms of change in QoL from T1 to T2 (the
primary analysis), from T1 to T3, and from T1 to T4.
Random intercept models, which utilise maximum-
likelihood estimation, provide more efficient estimates of
effects with unbalanced data than the traditional repeatedmeasures approach [67]. Multiple regression analyses will
be conducted using T1 data to identify demographic and
other factors that contribute to treatment outcome. Mul-
tiple comparisons will be used to test a priori hypotheses
and to conduct post-hoc testing, with the alpha rate ad-
justed using the Holm-Bonferroni method [68].
Discussion
This paper outlines the protocol for a multisite trial of a
novel online intervention for parents of children who
have recently completed treatment for cancer, entitled
Cascade. The Cascade program is unique because (i) it
targets parents and assesses the possible impact of the
intervention on children in the family and (ii) its online
delivery reduces geographical and physical isolation. The
planned RCT is methodologically rigorous since it fol-
lows gold-standard guidelines, includes both an active
and waitlist control, and employs strict treatment fidelity
assessments.
The technology used to deliver Cascade is an important
innovation, as it enables the provision of evidence-based
support to families dispersed across metropolitan, rural and
remote regions. Cascade is part of a broader telehealth
movement bringing about change in the way that mental
health care is delivered worldwide, in response to factors
such as geographical isolation and limitations of time and
resources [69-72]. There is growing evidence supporting
the potential of telepsychology in treating disorders such as
anxiety and depression [31,73,74]. Evidence suggests that
core aspects of CBT such as cognitive challenging, role-
playing and modelling, setting up behavioural experiments
and homework assignments, translate well over videocon-
ferencing [75]. Further, videoconferencing does not appear
to diminish facilitator competence, adherence, or patient
perceptions of rapport or empathy conveyed by the facilita-
tor [74]. However, as most ‘online therapies’ are self-guided
by the user with telephone/email-based support [76], few
manualised treatment programs or best-practice guidelines
exist to guide Cascade in aspects relating to therapy process
and online interaction. This may mean that facilitator prac-
tice effects occur across the study period, as the facilitator
gains competency in anticipating, and managing, challenges
in the videoconferencing environment.
This study is strengthened by the inclusion of both an
active and a waitlist control group. The waitlist group
controls for the possibilities that parent distress may dis-
sipate in the first weeks after treatment completion and/
or that clinical services may change or improve over the
recruitment period. However, the additional use of a
non-specific treatment arm (the PSG) is now considered
gold standard. Active controls better manage partici-
pants’ expectations of receiving some form of treatment.
This trial therefore enables an assessment of whether an
intensive, structured, skills-based intervention such as
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This question has important clinical, as well as economic
considerations, as the two strategies have different impli-
cations for resources, training and time commitments
required.
The planned treatment fidelity assessments will enable
an examination of the relative benefits of a structured,
CBT-based intervention when compared with a non-
directive, peer-support group model. It is possible and
likely that although the facilitator does not teach the
same structured, CBT-based coping skills in the PSG,
the peer groups may nevertheless spontaneously discuss
adaptive coping skills, unhelpful thinking styles, or stress
reduction strategies. The treatment fidelity assessment
will allow an examination of the extent to which such
skills-based discussion is facilitated, or directed, by the
Cascade facilitator, and the proportion of session time
spent discussing adaptive coping strategies. By conduct-
ing fidelity checks concurrently across the trial any sig-
nificant content overlap initiated by the facilitator will
be able to be corrected. This process will ensure that
despite some likely overlap in content, it will still be pos-
sible to distinguish between the two arms in terms of
mechanisms of change. This is critical in order to make
recommendations for future intervention design.
Despite its strengths, the Cascade study design also
has methodological vulnerabilities. The three-armed de-
sign will increase the time it takes to recruit sufficient
participant numbers. In addition, the 6-month follow-up
is another aspect of the study design that, although
methodologically important, may add complexities to
final data analyses. Participants may differ in terms of
psychosocial support services they receive in this time,
and the number of other parents of childhood cancer
survivors they come into contact with. Individual differ-
ences in additional support services and peer support is
likely to be important throughout the trial. These factors
will require careful monitoring and documentation, and
will need to be taken into account in data analyses/
interpretation.
In sum, Cascade is a selective preventative program with
the potential to avoid mental health problems in parents
and other family members by equipping parents with cop-
ing skills to manage the challenges of the survivorship
period. This study trials a new model of healthcare delivery
that can extend the reach of support to isolated populations
worldwide. If this study demonstrates significant improve-
ments in QoL, Cascade will be made available for use with
the parents of childhood cancer survivors across Australia,
with the potential to be delivered internationally as well.
Trial status
This is a clinical trial with ongoing patient recruitment. Re-
cruitment for this project commenced in September 2014and is expected to be completed by June 2016. This trial is
recorded under the number ACTRN12613000270718.
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